Skip Navigation


JAC Advance Access originally published online on April 19, 2008
Journal of Antimicrobial Chemotherapy 2008 62(1):116-121; doi:10.1093/jac/dkn124
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
62/1/116    most recent
dkn124v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Draghi, D. C.
Right arrow Articles by Sahm, D. F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Draghi, D. C.
Right arrow Articles by Sahm, D. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004–05 Prospective European Surveillance Initiative

Deborah C. Draghi1, Bret M. Benton2, Kevin M. Krause2, Clyde Thornsberry1, Chris Pillar1 and Daniel F. Sahm1,*

1 Eurofins Medinet, Inc., 13665 Dulles Technology Drive, Suite 200, Herndon, VA, USA 2 Theravance, Inc., 901 Gateway Boulevard, South San Francisco, CA, USA

Received 20 December 2007; returned 21 January 2008; revised 20 February 2008; accepted 27 February 2008

* Corresponding author. Tel: +1-703-480-2536; Fax: +1-703-480-2654; E-mail: daniel.sahm{at}eurofinsmedinet.com

Objectives: Telavancin is a novel semi-synthetic lipoglycopeptide currently in late-stage clinical development for the treatment of serious infections due to Gram-positive bacteria. The objective of this study was to provide a baseline prospective assessment of its in vitro activity against a large and diverse collection of Gram-positive clinical isolates from Europe and Israel.

Methods: Gram-positive clinical isolates, collected between October 2004 and December 2005 from 36 hospital laboratories in 15 countries, were tested by broth microdilution using CLSI methodology.

Results: In total, 3206 isolates were collected. Telavancin had potent activity against Staphylococcus aureus and coagulase-negative staphylococci (MIC range ≤0.015 to 2 mg/L), independent of resistance to methicillin or to multiple drugs. Telavancin had particularly strong activity against streptococcal isolates (MIC range ≤0.001 to 0.5 mg/L), including penicillin-resistant and multiple drug-resistant Streptococcus pneumoniae and erythromycin non-susceptible β-haemolytic and viridans group streptococci. Telavancin also had excellent activity against vancomycin-susceptible enterococci (MIC90 0.5 mg/L), and although its MICs were elevated against VanA strains (Enterococcus faecalis MIC90 8 mg/L and Enterococcus faecium MIC90 4 mg/L), its MIC90 was substantially lower than observed with available glycopeptides.

Conclusions: Telavancin has potent in vitro activity against contemporary Gram-positive clinical isolates from diverse geographic areas in Europe and Israel.

Keywords: susceptibility tests , Staphylococcus aureus , enterococci , Streptococcus spp.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.